​Tim Mayall, Ph.D.Head of Process Development​

Dr. Timothy Mayall joined EXUMA Biotechnology in June 2016 as Head of Process Development, where he leads all process development activities for the genetic modification of adoptive cellular therapies, including analytical methods and technology transfer and scale-up into GMP operations. From 2008 to 2013, Dr. Mayall was Senior Director of Research and Development at PaxVax Inc. Joining the early PaxVax team as Senior Director of Molecular Biology and Virology, he was responsible for the development of their adenovirus, type 4 platform for the development of vaccines against pandemic flu, anthrax and HIV. He was involved in INDs for all three programs, as well as supporting efforts to reintroduce a cholera vaccine. At PaxVax, he worked on novel cell substrates for vaccine production, resulting in the presentation of A549 cells for vaccine manufacture at a VERPAC meeting and a master file to support INDs. From 2000 to 2005, Dr. Mayall was at Canji Inc., a former Schering-Plough subsidiary, in molecular biology focusing on transcriptional regulation of adenoviral and therapeutic genes including early work on molecular switches and methods for adenovirus library construction. As one of the core members of the San Diego team, he worked on the final replication-defective virus/production cell line system for the treatment of bladder cancer. Dr. Mayall came to San Diego for his postdoctoral studies at the Salk Institute for Biological Studies in La Jolla where he later became a staff scientist. Dr. Mayall earned his BSc. (Hons) in Biochemistry from the University of Leeds and his Ph.D. in molecular biology from the University of London, United Kingdom.